Aardvark Therapeutics Faces Securities Class Action Lawsuit

The litigation, initiated by the Rosen Law Firm, targets disclosures made between February 13, 2025, and May 14, 2026. According to the complaint, Aardvark Therapeutics allegedly failed to disclose that ARD-101 possessed a lower safety profile than publicly represented. The suit contends that these omissions resulted in inflated clinical and regulatory prospects, ultimately causing financial harm to investors when the true nature of the drug's status reached the market.

Investors seeking to participate in the action may choose their own counsel or remain absent class members, as no class has yet been certified. The firm notes that serving as a lead plaintiff is not a prerequisite for sharing in any potential future recovery, though those interested in directing the litigation must meet the October filing deadline. The Rosen Law Firm is currently managing the case, and potential class members can access further information through their online portal or by contacting Phillip Kim directly.